A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib
D. Ross Camidge, Teresa Morán, Ingel Demedts, Heidrun Grosch, Kathryn F. Mileham, Julian R. Molina, Óscar Juan, Gerold Bepler, Jonathan W. Goldman, Keunchil Park, Johan Wallin, Sameera R. Wijayawardana, Xuejing Aimee Wang, Volker Wacheck, Egbert F. Smit
Topics & Concepts
ErlotinibMedicineEpidermal growth factor receptorErlotinib HydrochlorideInternal medicineLung cancerOncologyPhases of clinical researchCancerClinical trialLung Cancer Treatments and MutationsHepatocellular Carcinoma Treatment and PrognosisLiver physiology and pathology